Harbour Investments’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.6K Hold
6,000
– – ﹤0.01% 2918
2026
Q2
$14K Hold
6,000
– – ﹤0.01% 3163
2026
Q1
$13K Buy
+6,000
New +$14.9K ﹤0.01% 3124
2021
Q4
– Sell
-3,000
Closed -$4K – 3421
2021
Q3
$4K Buy
+3,000
New +$4.56K ﹤0.01% 3090

Other funds holding PLX

Harbour Investments's PLX Position: Q3 2026 in Review

Harbour Investments held its Protalix BioTherapeutics (PLX) position steady in Q3 2026 at 6,000 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2918.

Harbour Investments first reported a position in PLX in Q3 2021 and has held it in 4 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Harbour Investments held 6,000 shares of Protalix BioTherapeutics worth $16.6K as of Q3 2026.
  • Harbour Investments left its Protalix BioTherapeutics share count unchanged in Q3 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q3 2026, its #2918 holding.
  • Harbour Investments first reported a position in Protalix BioTherapeutics in Q3 2021 and has held it in 4 quarters since.
  • 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Harbour Investments's 13F filing for Q3 2026, filed 9 Nov 2026.